OPKO Health's ModeX Therapeutics licenses vaccine to Merck

9 March 2023

ModeX Therapeutics, an OPKO Health (Nasdaq: OPK) company, has entered into an exclusive worldwide license and collaboration agreement with Merck & Co (NYSE: MRK) for the development of MDX-2201, ModeX’ pre-clinical nanoparticle vaccine candidate targeting Epstein-Barr virus (EBV).

OPKO shares gained more than 7% to $1.14 following the announcement yesterday, after hitting a high of $1.32 earlier in the session.

“We are delighted to enter this collaboration with Merck to develop a vaccine against EBV, a virus that takes a profound toll on human health worldwide. Targeting four proteins used by EBV to infect cells, this vaccine candidate embodies the novel multitargeting approach developed by ModeX scientists,” said Dr Gary Nabel, president and chief executive of ModeX and Chief Innovation Officer of OPKO.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK